Perakslis Joins Precision for Medicine

August 13, 2013

By Bio-IT World Staff
August 13, 2013 | Eric Perakslis has joined Precision for Medicine, Inc. as Senior Advisor, Bioinformatics and Information Technology. Precision is a specialized scientific services company formed in 2012 to support next generation medical products. The company is headquartered in Bethesda, Md with offices in Frederick, Md and Cambridge, Mass. 
Perakslis will provide strategic and scientific guidance to the Precision leadership team in the development, acquisition, and execution of products and services in the rapidly evolving field of bioinformatics and health information technology. 
In addition to his role at Precision, Perakslis serves as the Executive Director of the Center for Biomedical Informatics and the Francis A. Countway Library of Medicine at Harvard Medical School. Prior to joining Harvard, Perakslis held the position of Chief Information Officer and Chief Scientist of Informatics at the Food and Drug Administration. Perakslis joined the FDA after a distinguished career in executive leadership at Johnson & Johnson, where his positions included Chief Information Officer, Director of Research Information Technology, and Director of Drug Discovery Research.
"Dr. Perakslis is an important addition to the Precision for Medicine leadership team," said Mark Clein, Precision President, in a statement. "Informatics and information technology are at the center of the advances taking place in drug development and Dr. Perakslis brings a rare combination of insight, experience, and success from his leadership experience in industry, government, and academia."
"The pressure to find a better and lower cost path for drug development is intensifying and the requirements of health reform only increase the need for specialized scientific expertise and health information technology," said Perakslis. "I look forward to working with the Precision for Medicine team to identify and develop innovative approaches, technologies, and partners to address these challenges and support next generation 'precision medicine'. "